Skip to Main Content

Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source.


Funding

The Vera and Joseph Dresner Foundation MDS Research Fund
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).

The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards

Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Learn More>>

Fast Funding for COVID-19 Science

If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.

Deadline: Fast Grant decisions are made in under 48 hours. Apply Now!

Apply for a Fast Funding grant now>>


DoD Lung Cancer Research Program Funding Opportunities

The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense LCRP to support innovative, high-impact lung cancer research.

Investigator-Initiated Translational Research Award - Pre-proposal Due: May 5, 2021
Clinical Translational Research Partnership Award - LOI Due: July 14, 2021



NCCN/AstraZeneca Initiative RFP in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC)

The intent of this RFP is to encourage NCCN Member Institutions to submit letters of intent (LOIs) describing concepts and ideas for developing, implementing and evaluating healthcare provider performance and/or healthcare quality improvement initiatives to improve patient care and outcomes in early-stage NSCLC.

Letter of Intent Deadline: May 3, 2021


Pfizer Global Medical Grants - NSCLC Therapy Management for Optimal Outcomes

Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.

Application Deadline: May 5, 2021


NCCN/Pfizer/Astellas Request for Proposals (RFP): Enzalutamide in the Treatment of Prostate Cancer

The overall aim of this RFP is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer.

Letter of Intent Due: May 14, 2021


The Cure Starts Now Foundation Research Grants

Research questions considered - Disease Impact: Does the study propose an intervention or clinical tool that will reduce the morbidity or mortality from or potentially find a cure for pediatric brain cancer? Innovation: Does the research study propose a novel approach or represent advancement in current treatment of pediatric brain cancer?

Application Deadline: June 1, 2021


Breast Cancer Alliance Young Investigator Grant

To encourage a commitment to breast cancer research, the BCA invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator Grant.

Internal LOI Deadline: June 1, 2021



Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)

This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries.

Application Deadline: June 2, 2021



Building Interdisciplinary Research Careers in Women's Health Program K12

This Program will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to the health of women and, where appropriate, the use of both sexes to better understand the influence of sex as a biological variable on health and disease.

Application Deadline: June 11, 2021



Administrative Supplements to Stimulate and Strengthen Global Cancer Survivorship Research

This NOSI is to announce an opportunity for supplemental funding to active, eligible NCI-funded grants and cooperative agreements to support global cancer survivorship research.

Application Deadline: June 11, 2021


NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC)

These FOAs support the NCI CPTAC managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community.

Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24): Application Deadline: June 30, 2021
Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24): Application Deadline: June 30, 2021
Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01): Application Deadline: July 30, 2021

NCCN/Pfizer Development of Talazoparib for Prostate Cancer RFP

This RFP is seeking proposals to advance the understanding of the mechanisms of action, underlying biology, and clinical activity of talazoparib in prostate cancer.

Letter of Intent Due: June 21, 2021



3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2)

Through this FOA, the NCI, as a part of its Beau Biden Cancer Moonshot Initiative, invites submission of applications requesting support for projects that will accelerate cancer research.

Application Deadline: June 30, 2021



Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional)

This FOA uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines.

Application Deadline: July 7, 2021


Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01)

The overarching goal of the RADx-UP initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities.

Application Deadline: July 7, 2021


Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program

The BMSF DCTCDP is a 2-year program designed to support the career development of early-stage investigator (as defined by NIH) physicians underrepresented in medicine, or physicians who have a demonstrated commitment to increasing diversity in clinical research, to become independent clinical trial investigators who are engaged in advancing health equity through their research and mentoring.

Application Deadline: July 2, 2021



Tobacco Regulatory Science (R01)

The purpose of this FOA is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Application Deadline: July 14, 2021


Centers on Telehealth Research for Cancer-Related Care (P50)

The purpose of this FOA is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment.

Application Deadline: July 20, 2021